Exploring how Guselkumab therapy affects liver and joint health in Psoriatic Arthritis patients with NAFLD
Elucidating Shared Mechanisms Contributing to Non-Alcoholic Fatty Liver Disease (NAFLD) and Psoriatic Arthritis (PsA) Disease Severity With Guselkumab Therapy
This study is testing how a treatment called Guselkumab can help people with Psoriatic Arthritis who also have liver problems, to see if it improves their joint and liver health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Sex | All |
| Sponsor | University of California, San Diego Academic / other |
| Drugs / interventions | Guselkumab, methotrexate |
| Locations | 1 site (San Diego, California) |
| Trial ID | NCT06586281 on ClinicalTrials.gov |
What this trial studies
This study investigates the shared mechanisms between Nonalcoholic Fatty Liver Disease (NAFLD) and Psoriatic Arthritis (PsA) severity, particularly focusing on the effects of Guselkumab therapy. It involves two visits for PsA patients who also have NAFLD and active disease signs, such as swollen joints or psoriatic plaques. The study aims to assess the impact of biological therapies on liver disorders, joints, and skin by utilizing imaging, metabolomics, and ultrasound-guided synovial biopsies to identify new molecular signatures and therapeutic targets.
Who should consider this trial
Good fit: Ideal candidates include adults diagnosed with PsA who have active disease signs and elevated liver fat consistent with NAFLD.
Not a fit: Patients with prior exposure to certain biologic therapies or other chronic liver diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for PsA patients with NAFLD, potentially reducing disease severity and enhancing overall health outcomes.
How similar studies have performed: While there is limited research specifically linking NAFLD and PsA, studies on biological therapies in similar contexts have shown promise, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults with diagnosis of PsA fulfilling the classification for PsA (CASPAR) criteria. 2. Must have: 1 or more swollen joint(s) and/or one or more active sites of enthesitis 3\. AND/OR 1 or more psoriatic plaques 4\. No changes in the regular medication regimen within the last three months, and no use of systemic and/or chronic steroids within 8 weeks leading up to the study. 5\. Overweight or obese by BMI ≥ 25.0 kg/m2 or ≥ 23.0 for Asian participants 6\. Patients are starting Guselkumab therapy for PsA as indicated by primary rheumatologist 7\. Elevated liver fat on controlled attenuation parameter (CAP) ≥ 288 dB/m, which is consistent with NAFLD after exclusion of secondary causes of liver disease. Exclusion Criteria: 1. Patients with prior exposure to IL12/23i, IL-17i, JAKi, or TYK2i. Patients with exposure to more than 2 TNFi. 2. Evidence of other causes of chronic liver disease * Hepatitis B as defined as presence of hepatitis B surface antigen (HBsAg). * Previous or current infection with Hepatitis C as defined by presence of hepatitis C virus Abin serum (anti-HCV Ab). * Autoimmune hepatitis as defined by anti-nuclear antibody (ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or previous response to immunosuppressive therapy. * Autoimmune cholestatic liver disorders as defined by elevation of alkaline phosphatase and anti-mitochondrial antibody of greater than 1:80 or liver histology consistent with primary biliary cirrhosis or elevation of alkaline phosphatase and liver histology consistent with sclerosing cholangitis. * Wilson disease as defined by ceruloplasmin below the limits of normal and liver histology consistent with Wilson disease. * Alpha-1-antitrypsin deficiency as defined by alpha-1-antitrypsin level less than normal and liver histology consistent with alpha-1-antitrypsin deficiency. * Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy and homozygosity for C282Y or compound heterozygosity for C282Y/H63D. * Drug-induced liver disease as defined on the basis of typical exposure and history. * Bile duct obstruction as shown by imaging studies. * History of gastrointestinal bypass surgery or ingestion of medications known to produce steatosis, such as corticosteroids, high-dose estrogen, tamoxifen, amiodarone or tetracycline in the previous 6 months. * Evidence of cirrhosis or previously known cirrhosis based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices * Presence of regular and/or excessive use of alcohol (defined as \>30g/day for males and \>15g/day for females) for a period longer than 2 years at any times in the last 10 years * Serum creatinine \> 2.0 mg/dL * The subject is a pregnant or nursing female or is planning to become pregnant * Life expectancy less than 5 years 3. History of known HIV infection
Where this trial is running
San Diego, California
- University of California, San Diego — San Diego, California, United States (Recruiting)
Study contacts
- Study coordinator: Mehrnaz Aghili
- Email: maghili@health.ucsd.edu
- Phone: 858-246-4721
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.